ABEO
ABEONA THERAPEUTICS INC.
NASDAQ · Healthcare · Biotechnology · US
$5.57
−0.36%Sep 18, 2026, 11:51 UTC
The U.S. FDA approved a drug that Abeona Therapeutics had licensed away, entitling Abeona to collect royalties.
Source:Sep 16, 2026, 11:30 UTC
Abeona Therapeutics activated University of Florida Health in Gainesville, Florida as the eighth Qualified Treatment Center for administering its ZEVASKYN gene-modified cellular sheets.
Source:Aug 13, 2026, 14:05 UTC
Abeona Therapeutics reported second-quarter revenue growth from its ZEVASKYN cell therapy launch, while noting operational challenges in patient scheduling and manufacturing that affected revenue recognition.
Jul 21, 2026, 11:30 UTC
Abeona Therapeutics Inc. activated Cincinnati Children's as the seventh Qualified Treatment Center for ZEVASKYN.
Source:Jun 12, 2026, 00:00 UTC
Michael Amoroso resigned from the Board of Directors of Abeona Therapeutics Inc., effective June 11, 2026.